Physician profile
Corwin Hill Brink
NPI 1356451793
$7,468.21
in general payments reported to CMS, 2019-2025
26 companies · $1,009 in 2025
The $1,009 reported for 2025 was more than what 81% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,552 · 2020: $811 · 2021: $992 · 2022: $1,384 · 2023: $1,240 · 2024: $481 · 2025: $1,009.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,730.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,730.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $1,046.04 | 2019-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $1,002.74 | 2019-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $916.86 | 2019-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $764.28 | 2019-2022 | |
| Abbvie INC. | $740.49 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $354.37 | 2020-2025 | Caplyta |
| Allergan, INC. | $312.37 | 2019-2020 | |
| Tris Pharma INC | $274.75 | 2023-2025 | Dyanavel Xr |
| Vanda Pharmaceuticals INC. | $237.30 | 2019-2025 | Hetlioz, Fanapt |
| Janssen Pharmaceuticals, INC | $236.08 | 2019-2023 | Invega Trinza, Invega Sustenna |
| Idorsia Pharmaceuticals US INC | $202.02 | 2023-2024 | Quviviq |
| Alkermes, INC. | $201.12 | 2020-2023 | Lybalvi, Aristada |
| Ironshore Pharmaceuticals INC. | $182.64 | 2019-2024 | |
| Neurocrine Biosciences, INC. | $174.07 | 2019-2023 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $151.38 | 2021-2024 | Qelbree, Qelbree |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $124.08 | 2019 | |
| Axsome Therapeutics, INC. | $102.87 | 2025 | Auvelity |
| Almatica Pharma LLC | $93.80 | 2023 | Loreev Xr |
| Teva Pharmaceuticals USA, INC. | $76.97 | 2021-2023 | Austedo Xr, Austedo |
| Alfasigma USA, INC. | $74.95 | 2020-2022 | |
| Bausch Health US, LLC | $66.63 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $49.45 | 2019 | |
| Corium, LLC | $30.75 | 2023 | Azstarys |
| Eisai INC. | $18.10 | 2020 | |
| Neuronetics, INC. | $17.63 | 2019 | |
| Adlon Therapeutics L.P. | $16.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corwin Brink listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.